Celemics Inc (331920.KQ) stock: key figures, P/E, revenue and dividend

Energy · Coal & Consumable Fuels · South Korea

Price
8,700.00 KRW
Market cap
97.28 bn KRW
P/E (2025)
–
P/S (2025)
16.87
Dividend yield
0.00 %
Net margin
-69.98 %
Return on equity (ROE)
-17.54 %
Return on assets (ROA)
-16.54 %

Celemics Inc financials

Fiscal year20242025
Revenue6.72 bn KRW5.77 bn KRW
Gross profit3.68 bn KRW2.87 bn KRW
Operating income-1.90 bn KRW-3.32 bn KRW
EBIT12.29 bn KRW-4.02 bn KRW
Net income12.27 bn KRW-4.04 bn KRW
Diluted EPS – continuing operations1,502.48 KRW-494.41 KRW

Full history since 2015, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Celemics Inc

Celemics, Inc. designs, manufactures, and distributes sequencing kits in South Korea. The company offers whole exome sequencing panels; NGS target enrichment panels; customized and ready-to-use enrichment panels; and modular accessories, including library preparation kits, double standard Cdna synthesis, hybridization enhancer, celan-up and streptavidin beads, CeleNM beads, and polymerase. It also provides celemics analysis, whole exome sequencing, customized NGS panels, sequencing, bioinformatics, biopharma, and custom NGS assay development services. Its products are used in oncology, liquid biopsy, biopharma solutions, inherited diseases, pharmacogenomics, virus research, agrigenomics, RNA sequencing, epigenetics, metagenomic sequencing, antibody discovery, and bioinformatics applications. The company was founded in 2010 and is headquartered in Seoul, South Korea.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 30.10.2026. Details in the risk notice.